{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:59:28Z","timestamp":1780984768885,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Chinese National Key Technology R&D Program, Ministry of Science and Technology","award":["(2017YFC0907601"],"award-info":[{"award-number":["(2017YFC0907601"]}]},{"name":"the Chinese National Key Technology R&D Program, Ministry of Science and Technology","award":["2017YFC0907605)"],"award-info":[{"award-number":["2017YFC0907605)"]}]},{"name":"the CAMS Innovation Fund for Medical Sciences","award":["(2021-I2M-1-005"],"award-info":[{"award-number":["(2021-I2M-1-005"]}]},{"name":"the CAMS Innovation Fund for Medical Sciences","award":["2022-I2M-1-004"],"award-info":[{"award-number":["2022-I2M-1-004"]}]},{"name":"the CAMS Innovation Fund for Medical Sciences","award":["2023-I2M-2-005"],"award-info":[{"award-number":["2023-I2M-2-005"]}]},{"name":"the CAMS Innovation Fund for Medical Sciences","award":["2023-I2M-C&T-B-018)"],"award-info":[{"award-number":["2023-I2M-C&T-B-018)"]}]},{"name":"the National High Level Hospital Clinical Research Funding","award":["(2022-PUMCH-A-227"],"award-info":[{"award-number":["(2022-PUMCH-A-227"]}]},{"name":"the National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-013"],"award-info":[{"award-number":["2022-PUMCH-B-013"]}]},{"name":"the National High Level Hospital Clinical Research Funding","award":["2025-PUMCH-D-001)"],"award-info":[{"award-number":["2025-PUMCH-D-001)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10067-026-07945-y","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:15:36Z","timestamp":1776064536000},"page":"3485-3495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-to-moderate dose glucocorticoids in primary Sj\u00f6gren\u2019s syndrome patients on hydroxychloroquine\/iguratimod therapy: a target trial emulation study"],"prefix":"10.1007","volume":"45","author":[{"given":"Xiangpeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuliang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0215-9176","authenticated-orcid":false,"given":"Xiaomei","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"7945_CR1","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1093\/rheumatology\/kez052","volume":"60","author":"G Nocturne","year":"2021","unstructured":"Nocturne G, Pontarini E, Bombardieri M, Mariette X (2021) Lymphomas complicating primary Sj\u00f6gren\u2019s syndrome: from autoimmunity to lymphoma. Rheumatology (Oxford) 60:3513\u20133521. https:\/\/doi.org\/10.1093\/rheumatology\/kez052","journal-title":"Rheumatology (Oxford)"},{"key":"7945_CR2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMcp1702514","volume":"378","author":"X Mariette","year":"2018","unstructured":"Mariette X, Criswell LA (2018) Primary Sj\u00f6gren\u2019s syndrome. N Engl J Med 378:931\u2013939. https:\/\/doi.org\/10.1056\/NEJMcp1702514","journal-title":"N Engl J Med"},{"key":"7945_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.47","volume":"2","author":"P Brito-Zer\u00f3n","year":"2016","unstructured":"Brito-Zer\u00f3n P, Baldini C, Bootsma H et al (2016) Sj\u00f6gren syndrome. Nat Rev Dis Primers 2:16047. https:\/\/doi.org\/10.1038\/nrdp.2016.47","journal-title":"Nat Rev Dis Primers"},{"key":"7945_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/s0140-6736(05)66990-5","volume":"366","author":"RI Fox","year":"2005","unstructured":"Fox RI (2005) Sj\u00f6gren\u2019s syndrome. Lancet 366:321\u2013331. https:\/\/doi.org\/10.1016\/s0140-6736(05)66990-5","journal-title":"Lancet"},{"key":"7945_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/clep.S47399","volume":"6","author":"R Patel","year":"2014","unstructured":"Patel R, Shahane A (2014) The epidemiology of Sj\u00f6gren\u2019s syndrome. Clin Epidemiol 6:247\u2013255. https:\/\/doi.org\/10.2147\/clep.S47399","journal-title":"Clin Epidemiol"},{"key":"7945_CR6","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1136\/annrheumdis-2014-205375","volume":"74","author":"B Qin","year":"2015","unstructured":"Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, Zhong R (2015) Epidemiology of primary Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 74:1983\u20131989. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205375","journal-title":"Ann Rheum Dis"},{"key":"7945_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","volume":"79","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Bombardieri S et al (2020) EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies. Ann Rheum Dis 79:3\u201318. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216114","journal-title":"Ann Rheum Dis"},{"key":"7945_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41584-021-00634-x","volume":"17","author":"R Seror","year":"2021","unstructured":"Seror R, Nocturne G, Mariette X (2021) Current and future therapies for primary Sj\u00f6gren syndrome. Nat Rev Rheumatol 17:475\u2013486. https:\/\/doi.org\/10.1038\/s41584-021-00634-x","journal-title":"Nat Rev Rheumatol"},{"key":"7945_CR9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/nrrheum.2016.100","volume":"12","author":"A Saraux","year":"2016","unstructured":"Saraux A, Pers J-O, Devauchelle-Pensec V (2016) Treatment of primary Sj\u00f6gren syndrome. Nat Rev Rheumatol 12:456\u2013471. https:\/\/doi.org\/10.1038\/nrrheum.2016.100","journal-title":"Nat Rev Rheumatol"},{"key":"7945_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2020-218467","volume":"80","author":"R Felten","year":"2021","unstructured":"Felten R, Devauchelle-Pensec V, Seror R et al (2021) Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis 80:329\u2013338. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218467","journal-title":"Ann Rheum Dis"},{"key":"7945_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s0140-6736(21)02251-0","volume":"399","author":"SJ Bowman","year":"2022","unstructured":"Bowman SJ, Fox R, D\u00f6rner T et al (2022) Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet 399:161\u2013171. https:\/\/doi.org\/10.1016\/s0140-6736(21)02251-0","journal-title":"Lancet"},{"key":"7945_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.41451","volume":"5","author":"J He","year":"2022","unstructured":"He J, Chen J, Miao M et al (2022) Efficacy and safety of low-dose interleukin 2 for primary Sj\u00f6gren syndrome: a randomized clinical trial. JAMA Netw Open 5:e2241451. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.41451","journal-title":"JAMA Netw Open"},{"key":"7945_CR13","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/s0140-6736(22)01536-7","volume":"400","author":"S Dyball","year":"2022","unstructured":"Dyball S, Parker B, Bruce IN (2022) Ianalumab in Sj\u00f6gren\u2019s syndrome: what can we learn from lupus trials? Lancet 400:807\u2013808. https:\/\/doi.org\/10.1016\/s0140-6736(22)01536-7","journal-title":"Lancet"},{"issue":"Suppl 112","key":"7945_CR14","first-page":"121","volume":"36","author":"A Flores-Ch\u00e1vez","year":"2018","unstructured":"Flores-Ch\u00e1vez A, Kostov B, Solans R et al (2018) Severe, life-threatening phenotype of primary Sj\u00f6gren\u2019s syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clin Exp Rheumatol 36(Suppl 112):121\u2013129","journal-title":"Clin Exp Rheumatol"},{"key":"7945_CR15","doi-asserted-by":"publisher","DOI":"10.7326\/annals-24-01871","author":"MA Hern\u00e1n","year":"2025","unstructured":"Hern\u00e1n MA, Dahabreh IJ, Dickerman BA, Swanson SA (2025) The target trial framework for causal inference from observational data: why and when is it helpful? Ann Intern Med. https:\/\/doi.org\/10.7326\/annals-24-01871","journal-title":"Ann Intern Med"},{"key":"7945_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.36023","volume":"6","author":"HJ Hansford","year":"2023","unstructured":"Hansford HJ, Cashin AG, Jones MD et al (2023) Reporting of observational studies explicitly aiming to emulate randomized trials: a systematic review. JAMA Netw Open 6:e2336023. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.36023","journal-title":"JAMA Netw Open"},{"key":"7945_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10067-022-06426-2","volume":"42","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Qiao L, Zhang L et al (2023) Renal tubular acidosis and associated factors in patients with primary Sj\u00f6gren\u2019s syndrome: a registry-based study. Clin Rheumatol 42:431\u2013441. https:\/\/doi.org\/10.1007\/s10067-022-06426-2","journal-title":"Clin Rheumatol"},{"key":"7945_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/0961203319889666","volume":"29","author":"D Xu","year":"2020","unstructured":"Xu D, Zhao S, Li Q et al (2020) Characteristics of Chinese patients with primary Sj\u00f6gren\u2019s syndrome: preliminary report of a multi-centre registration study. Lupus 29:45\u201351. https:\/\/doi.org\/10.1177\/0961203319889666","journal-title":"Lupus"},{"key":"7945_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.15284","volume":"27","author":"L Yueting","year":"2024","unstructured":"Yueting L, Lin Q, Jian X et al (2024) Long-term survival analysis of patients with primary Sj\u00f6gren\u2019s syndrome in China: a multicenter retrospective cohort study. Int J Rheum Dis 27:e15284. https:\/\/doi.org\/10.1111\/1756-185x.15284","journal-title":"Int J Rheum Dis"},{"key":"7945_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K (2011) mice: Multivariate imputation by chained equations in R. J Stat Softw 45:1\u201367. https:\/\/doi.org\/10.18637\/jss.v045.i03","journal-title":"J Stat Softw"},{"key":"7945_CR21","unstructured":"Greifer N. WeightIt: weighting for covariate balance in observational studies. 2024\u201311\u201305 ed2024."},{"key":"7945_CR22","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2020.7819","volume":"323","author":"LE Thomas","year":"2020","unstructured":"Thomas LE, Li F, Pencina MJ (2020) Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. JAMA 323:2417\u20132418. https:\/\/doi.org\/10.1001\/jama.2020.7819","journal-title":"JAMA"},{"key":"7945_CR23","unstructured":"Kazuki Yoshida, Alexander Bartel, Jonathan J Chipman, et al. tableone: create \u2018table 1' to describe baseline characteristics with or without propensity score weights. 0.13.2 ed2022."},{"key":"7945_CR24","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput 38:1228\u20131234. https:\/\/doi.org\/10.1080\/03610910902859574","journal-title":"Commun Stat Simul Comput"},{"key":"7945_CR25","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083\u20133107. https:\/\/doi.org\/10.1002\/sim.3697","journal-title":"Stat Med"},{"key":"7945_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2013.00863","volume":"4","author":"D Lakens","year":"2013","unstructured":"Lakens D (2013) Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol 4:863. https:\/\/doi.org\/10.3389\/fpsyg.2013.00863","journal-title":"Front Psychol"},{"key":"7945_CR27","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences (2nd ed: Statistical power analysis for the behavioral sciences; 1988."},{"key":"7945_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrrheum.2012.53","volume":"8","author":"M Ramos-Casals","year":"2012","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Sis\u00f3-Almirall A, Bosch X, Tzioufas AG (2012) Topical and systemic medications for the treatment of primary Sj\u00f6gren\u2019s syndrome. Nat Rev Rheumatol 8:399\u2013411. https:\/\/doi.org\/10.1038\/nrrheum.2012.53","journal-title":"Nat Rev Rheumatol"},{"key":"7945_CR29","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/ard.57.8.464","volume":"57","author":"M Izumi","year":"1998","unstructured":"Izumi M, Eguchi K, Nakamura H, Takagi Y, Kawabe Y, Nakamura T (1998) Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 57:464\u2013469. https:\/\/doi.org\/10.1136\/ard.57.8.464","journal-title":"Ann Rheum Dis"},{"key":"7945_CR30","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2169\/internalmedicine.38.938","volume":"38","author":"S Miyawaki","year":"1999","unstructured":"Miyawaki S, Nishiyama S, Matoba K (1999) Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sj\u00f6gren\u2019s syndrome. Intern Med 38:938\u2013943. https:\/\/doi.org\/10.2169\/internalmedicine.38.938","journal-title":"Intern Med"},{"key":"7945_CR31","first-page":"149","volume":"11","author":"PC Fox","year":"1993","unstructured":"Fox PC, Datiles M, Atkinson JC et al (1993) Prednisone and piroxicam for treatment of primary Sj\u00f6gren\u2019s syndrome. Clin Exp Rheumatol 11:149\u2013156","journal-title":"Clin Exp Rheumatol"},{"key":"7945_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/ard.2006.052647","volume":"66","author":"J Pijpe","year":"2007","unstructured":"Pijpe J, Kalk WW, Bootsma H, Spijkervet FK, Kallenberg CG, Vissink A (2007) Progression of salivary gland dysfunction in patients with Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 66:107\u2013112. https:\/\/doi.org\/10.1136\/ard.2006.052647","journal-title":"Ann Rheum Dis"},{"key":"7945_CR33","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1136\/ard.2009.110619","volume":"69","author":"R Seror","year":"2010","unstructured":"Seror R, Ravaud P, Bowman SJ et al (2010) EULAR Sj\u00f6gren\u2019s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 69:1103\u20131109. https:\/\/doi.org\/10.1136\/ard.2009.110619","journal-title":"Ann Rheum Dis"},{"key":"7945_CR34","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/ard.2010.143743","volume":"70","author":"R Seror","year":"2011","unstructured":"Seror R, Ravaud P, Mariette X et al (2011) EULAR Sj\u00f6gren\u2019s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 70:968\u2013972. https:\/\/doi.org\/10.1136\/ard.2010.143743","journal-title":"Ann Rheum Dis"},{"key":"7945_CR35","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/s2665-9913(23)00340-5","volume":"6","author":"Y Nguyen","year":"2024","unstructured":"Nguyen Y, Nocturne G, Henry J et al (2024) Identification of distinct subgroups of Sj\u00f6gren\u2019s disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts. Lancet Rheumatol 6:e216\u2013e225. https:\/\/doi.org\/10.1016\/s2665-9913(23)00340-5","journal-title":"Lancet Rheumatol"},{"key":"7945_CR36","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00296-021-04927-y","volume":"41","author":"A Collins","year":"2021","unstructured":"Collins A, Lendrem D, Wason J et al (2021) Revisiting the JOQUER trial: stratification of primary Sj\u00f6gren\u2019s syndrome and the clinical and interferon response to hydroxychloroquine. Rheumatol Int 41:1593\u20131600. https:\/\/doi.org\/10.1007\/s00296-021-04927-y","journal-title":"Rheumatol Int"},{"key":"7945_CR37","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/s2665-9913(19)30042-6","volume":"1","author":"JR Tarn","year":"2019","unstructured":"Tarn JR, Howard-Tripp N, Lendrem DW et al (2019) Symptom-based stratification of patients with primary Sj\u00f6gren\u2019s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol 1:e85\u2013e94. https:\/\/doi.org\/10.1016\/s2665-9913(19)30042-6","journal-title":"Lancet Rheumatol"},{"key":"7945_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23472-7","volume":"12","author":"P Soret","year":"2021","unstructured":"Soret P, Le Dantec C, Desvaux E et al (2021) A new molecular classification to drive precision treatment strategies in primary Sj\u00f6gren\u2019s syndrome. Nat Commun 12:3523. https:\/\/doi.org\/10.1038\/s41467-021-23472-7","journal-title":"Nat Commun"},{"key":"7945_CR39","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","volume":"30","author":"EW St Clair","year":"2024","unstructured":"St Clair EW, Baer AN, Ng WF et al (2024) CD40 ligand antagonist dazodalibep in Sj\u00f6gren\u2019s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med 30:1583\u20131592. https:\/\/doi.org\/10.1038\/s41591-024-03009-3","journal-title":"Nat Med"},{"key":"7945_CR40","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/art.38100","volume":"65","author":"AV Goules","year":"2013","unstructured":"Goules AV, Tatouli IP, Moutsopoulos HM, Tzioufas AG (2013) Clinically significant renal involvement in primary Sj\u00f6gren\u2019s syndrome: clinical presentation and outcome. Arthritis Rheum 65:2945\u20132953. https:\/\/doi.org\/10.1002\/art.38100","journal-title":"Arthritis Rheum"},{"key":"7945_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-015-0858-x","volume":"17","author":"RD Evans","year":"2016","unstructured":"Evans RD, Laing CM, Ciurtin C, Walsh SB (2016) Tubulointerstitial nephritis in primary Sj\u00f6gren syndrome: clinical manifestations and response to treatment. BMC Musculoskelet Disord 17:2. https:\/\/doi.org\/10.1186\/s12891-015-0858-x","journal-title":"BMC Musculoskelet Disord"},{"key":"7945_CR42","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1136\/annrheumdis-2011-200384","volume":"71","author":"S Arends","year":"2012","unstructured":"Arends S, Grootscholten C, Derksen RH et al (2012) Long-term follow-up of a randomised controlled trial of azathioprine\/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis 71:966\u2013973. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200384","journal-title":"Ann Rheum Dis"},{"key":"7945_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ph17081044","author":"AS Juncker","year":"2024","unstructured":"Juncker AS, Appenzeller S, de Souza JM (2024) Central nervous system involvement in systemic autoimmune rheumatic diseases-diagnosis and treatment. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph17081044","journal-title":"Pharmaceuticals (Basel)"},{"key":"7945_CR44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/rheumatology\/kev354","volume":"55","author":"AG Singh","year":"2016","unstructured":"Singh AG, Singh S, Matteson EL (2016) Rate, risk factors and causes of mortality in patients with Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 55:450\u2013460. https:\/\/doi.org\/10.1093\/rheumatology\/kev354","journal-title":"Rheumatology (Oxford)"},{"key":"7945_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e38803","volume":"10","author":"T Zhao","year":"2024","unstructured":"Zhao T, Zhang R, Li Z, Qin D, Wang X (2024) Novel and potential future therapeutic options in Sj\u00f6gren\u2019s syndrome. Heliyon 10:e38803. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38803","journal-title":"Heliyon"},{"key":"7945_CR46","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMra2033982","volume":"385","author":"S Berentsen","year":"2021","unstructured":"Berentsen S, Barcellini W (2021) Autoimmune hemolytic anemias. N Engl J Med 385:1407\u20131419. https:\/\/doi.org\/10.1056\/NEJMra2033982","journal-title":"N Engl J Med"},{"key":"7945_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110716","volume":"123","author":"F Sun","year":"2023","unstructured":"Sun F, Tang Q, Cheng W, Xie X, Li F, Chen J (2023) Characteristics and treatment responses of immune thrombocytopenia in patients with primary Sj\u00f6gren syndrome. Int Immunopharmacol 123:110716. https:\/\/doi.org\/10.1016\/j.intimp.2023.110716","journal-title":"Int Immunopharmacol"},{"key":"7945_CR48","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","volume":"81","author":"R Seror","year":"2022","unstructured":"Seror R, Baron G, Camus M et al (2022) Development and preliminary validation of the Sj\u00f6gren\u2019s tool for assessing response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 81:979\u2013989. https:\/\/doi.org\/10.1136\/annrheumdis-2021-222054","journal-title":"Ann Rheum Dis"},{"key":"7945_CR49","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/s2665-9913(21)00122-3","volume":"3","author":"S Arends","year":"2021","unstructured":"Arends S, de Wolff L, van Nimwegen JF et al (2021) Composite of relevant endpoints for Sj\u00f6gren\u2019s syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatol 3:e553\u2013e562. https:\/\/doi.org\/10.1016\/s2665-9913(21)00122-3","journal-title":"Lancet Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-07945-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-07945-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-07945-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:24:34Z","timestamp":1780982674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-07945-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7945"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-07945-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was approved by the Ethics Committee of Peking Union Medical College Hospital (approval number: JS-2038). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}